Hydraulic Cylinders Imports Investigated: Tariffs Looming?
Published Date: 10/14/2026
Notice
Summary
The U.S. government is looking into whether imports of linear hydraulic cylinders from Canada, China, India, Mexico, and South Korea are hurting American businesses by being sold unfairly cheap or getting government help. If confirmed, this could lead to new rules or tariffs to protect U.S. makers. Companies involved should watch for updates soon, as final decisions and possible changes are on the way.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Preliminary finding: U.S. makers harmed
The U.S. International Trade Commission determined there is a reasonable indication that a U.S. industry is materially injured by imports of linear hydraulic cylinders from Canada, China, India, Mexico, and South Korea. The Commission states imports from China, India, and Mexico are alleged to be subsidized and imports from Canada, China, India, Mexico, and South Korea are alleged to be sold at less than fair value; the Commission completed and filed these determinations on October 9, 2026 (USITC Publication 5800).
Antidumping and countervailing probes opened
Countervailing duty investigations (Nos. 701-TA-802, -803, -804) and antidumping duty investigations (Nos. 731-TA-1799, -1800, -1801, -1802, -1803) into linear hydraulic cylinders were instituted effective July 29, 2026. The Commission has commenced the final phase and will publish a final phase notice after the Department of Commerce issues the specified preliminary or final determinations.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-21100, Certain Systems, Devices, Software, Compositions, Chemicals, and Laboratory Supplies for Studying Proteins; Notice of Commission Determination Not To Review an Initial Determination Finding the Sole Respondent in This Investigation in Default; Request for Written Submissions on Remedy, the Public Interest, and Bonding
The U.S. International Trade Commission has decided not to reconsider its finding that Nanomics Biotechnology, a company from China, failed to respond in a case about protein study tools. Now, the Commission is asking for ideas on how to fix the problem, protect the public, and handle money matters. This affects companies importing or selling these protein research products in the U.S. and could lead to new rules or restrictions soon.
2026-20993, Certain Vertical Power Delivery Systems, Components Thereof, and Computing Systems Containing the Same; Notice of Institution of Investigation
Vicor Corporation has asked the U.S. International Trade Commission to investigate certain vertical power delivery systems and related computing parts for patent infringement. This could lead to import bans and sales restrictions in the U.S., affecting companies selling these products. The investigation started in October 2026 and might impact the market and money flow soon.
2026-20918, Non-Refillable Steel Cylinders From China; Determinations
The U.S. International Trade Commission decided to keep special taxes on non-refillable steel cylinders from China because removing them could hurt American businesses. This means importers from China will still pay extra fees, helping protect U.S. manufacturers. The decision was finalized in October 2026 and signals ongoing costs for importers and continued support for local industry.
2026-20932, Notice of Receipt of Complaint; Solicitation of Comments Relating to the Public Interest
The U.S. International Trade Commission got a complaint about certain spectral flow cytometry systems, claiming some companies might be breaking import rules. They want your thoughts on how this could affect the public before deciding on actions like blocking sales or imports. If you’re involved or interested, now’s the time to speak up—this could impact businesses and products soon!
2026-20752, Certain Hydrodermabrasion Systems and Components Thereof; Notice of Vacatur of the Commission's Final Determination and Mootness of the Investigation by the Federal Circuit Due to Patent Expiration
The U.S. International Trade Commission's investigation into certain hydrodermabrasion systems has been canceled because the key patent expired. This affects companies like HydraFacial and Cartessa, ending any legal battles over these products. The case officially closed in March 2026, so no money penalties or import bans will happen now.
2026-20614, Forged Steel Fittings From India and South Korea; Cancellation of Hearing for Antidumping and Countervailing Duty Reviews
The U.S. International Trade Commission has canceled the public hearing for the review of antidumping and countervailing duties on forged steel fittings from India and South Korea. This change affects companies like Bonney Forge and related unions, who will now answer questions without a formal hearing. The cancellation speeds up the process, with no immediate money changes but keeps the review on track.
Previous / Next Documents
Previous: 2026-20986, Records Schedules; Availability and Request for Comments
The National Archives is sharing new plans from federal agencies about which old records they want to toss because they’re no longer needed. They’re asking the public to check out these plans and share thoughts by November 30, 2026. This helps keep government record-keeping smart and efficient, with no extra costs for you!
Next: 2026-20989, Advisory Committee; Cellular, Tissue, and Gene Therapies Advisory Committee; Renewal
The FDA is renewing its Cellular, Tissue, and Gene Therapies Advisory Committee for two more years, keeping it active until October 28, 2028. This committee helps the FDA make sure new cell, tissue, and gene therapies are safe and effective for people. If you’re involved in these cutting-edge treatments, this renewal means expert advice will keep guiding the FDA’s decisions without interruption.